SeraCare Life Sciences, Inc.
37 Birch Street
Milford,
MA 01757
United States - Map
Phone: 508-244-6400
Fax: 508-634-3394
Web Site: http://www.seracare.com
| SeraCare Life Sciences, Inc., a global life sciences company, provides products and services to facilitate the discovery, development, and production of human diagnostics and therapeutics. It develops and manufactures biologically-based products and offers a range of related services, backed by expertise in virology, serology, immunology, and molecular biology. The companys portfolio includes diagnostic controls, plasma-derived reagents, and molecular biomarkers, as well as biobanking and contract research services. Its Diagnostic & Biopharmaceutical Products segment provides controls and panels used for the evaluation and quality control of infectious disease tests in hospital and clinical labs, and blood banks, as well as by in vitro diagnostic manufacturers; and reagents and bioprocessing products, including biological materials for use in the research, development, and manufacture of human and animal diagnostics, therapeutics, and vaccines. SeraCares BioServices segment offers biobanking, sample processing, and testing services for research and clinical trials; and contract research services in molecular biology, virology, and biochemistry. The company was founded in 1984 and is headquartered in Milford, Massachusetts. |
|
| Key Statistics |
| |
| | Pay | Exercised | Ms. Susan L. N. Vogt , 55
Chief Exec. Officer, Pres |
$
599.00K | N/A | Mr. Gregory A. Gould CPA, 42
Chief Financial Officer, Principal Accounting Officer, Sec. and Treasurer |
$
428.00K | N/A | Mr. William J. Smutny , 59
VP of Sales & Marketing |
$
233.00K | N/A | Mr. Ronald R. Dilling , 54
VP of Manufacturing Operations |
$
248.00K | N/A | Ms. Katheryn E. Shea , 41
VP of BioServices Operations |
$
209.00K | N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
1.10% Nasdaq 
0.11 (3.03%) 
Profile
